Santhera Pharmaceuticals (SPHDF.OB) has announced positive findings from the LIONHEART study, which confirms that vamorolone functions uniquely as a mineralocorticoid receptor antagonist, setting it apart from other corticosteroids.
The LIONHEART study was an open-label, randomized, placebo- and eplerenone-controlled trial involving 30 healthy adult male participants. The study successfully met its primary endpoint by showing a statistically significant increase in the urinary sodium/potassium ratio in the vamorolone group compared to the placebo group following a fludrocortisone challenge. This elevated urine ratio provides clinical evidence of vamorolone's distinctive mode of action as a mineralocorticoid receptor antagonist (MRA) in humans.
Cardiac complications, such as cardiomyopathy, are a leading cause of morbidity and mortality in boys with Duchenne muscular dystrophy (DMD). Although treatment with corticosteroids and ACE inhibitors has been shown to delay the onset of cardiomyopathy, the addition of MRAs, including eplerenone, to the standard of care has also demonstrated improvements in left ventricular systolic dysfunction, with earlier initiation providing greater benefits.
